ArriVent BioPharma Inc AVBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $16.80
- Day Range
- $16.76–17.51
- 52-Week Range
- $14.35–23.13
- Bid/Ask
- $10.80 / $27.39
- Market Cap
- $577.10 Mil
- Volume/Avg
- 23,943 / 184,255
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team’s deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 40
- Website
- https://arrivent.com
Valuation
|
Metric
|
AVBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AVBP
|
|---|---|
Quick Ratio | 13.02 |
Current Ratio | 13.76 |
Interest Coverage | — |
Quick Ratio
AVBP
Profitability
|
Metric
|
AVBP
|
|---|---|
Return on Assets (Normalized) | −37.67% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AVBP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xlfrhspp | Pbs | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gqvyvdxf | Jxzky | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mcttftpcg | Rtmbwd | $103.7 Bil | |
MRNA
| Moderna Inc | Rztctlhj | Mskb | $47.9 Bil | |
ARGX
| argenx SE ADR | Zjlhshdm | Cffq | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Hfqvjgrj | Rwgpr | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jjdqfpkz | Nlhpqgm | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sdybgvnf | Vlwbfym | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qkmnjjtymb | Yfsjc | $12.8 Bil | |
INCY
| Incyte Corp | Rhzzqyk | Wlprl | $12.1 Bil |